Community-Based Provision of Statin and Aspirin After the Detection of Coronary Artery Calcium Within a Community-Based Screening Cohort  by Taylor, Allen J. et al.
M
c
c
t
v
d
g
A
c
p
e
F
M
H
d
P
D
a
2
Journal of the American College of Cardiology Vol. 51, No. 14, 2008
© 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00
PCLINICAL RESEARCH Coronary Artery Disease
Community-Based Provision of Statin and
Aspirin After the Detection of Coronary Artery
Calcium Within a Community-Based Screening Cohort
Allen J. Taylor, MD,*† Jody Bindeman, BSN,* Irwin Feuerstein, MD,*† Toan Le, SCD,*
Kelly Bauer, BSN,* Carole Byrd, LVN,* Holly Wu, MD,* Patrick G. O’Malley, MD, MPH*†
Washington, DC; and Bethesda, Maryland
Objectives We examined the association of coronary artery calcium (CAC) detected on a screening exam with subsequent
statin and aspirin usage in a healthy male screening cohort.
Background Whether the presence of CAC, an independent predictor of coronary heart disease outcomes, alters clinical man-
agement, such as the use of preventive medications, is unknown.
Methods Men (n  1,640) ages 40 to 50 years (mean 42 years) were screened for coronary heart disease risk factors
and CAC. The CAC scores and risk factors were reported to patients, and results were made available in the elec-
tronic medical record; however, medications were not prescribed or recommended by the study. During up to 6
years of subsequent annual structured telephone follow-up, we observed the community-based initiation and
persistence of aspirin and statin therapy.
Results A progressive increase in the incidence of pharmacotherapy was noted over time such that those with CAC were
3 times more likely to receive a statin (48.5% vs. 15.5%, p  0.001) and also significantly more likely to receive
aspirin (53.0% vs. 32.3%; p  0.001) than those without CAC. In multivariable models controlling for National
Cholesterol Education Program risk variables and baseline medication use, CAC was strongly and independently
associated with use of either statin (odds ratio [OR] 3.53; 95% confidence interval [CI] 2.66 to 4.69), aspirin (OR
3.05; 95% CI 2.30 to 4.05) or both (OR 6.97; 95% CI 4.81 to 10.10).
Conclusions In this prospective cohort, the presence of coronary calcification was associated with an independent 3-fold
greater likelihood of statin and aspirin usage. (J Am Coll Cardiol 2008;51:1337–41) © 2008 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.11.069d
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multiple prospective observational studies have shown that
oronary artery calcium (CAC) is an independent marker of
ardiovascular risk providing incremental prognostic value over
raditional and emerging risk markers (1). The incremental
alue of CAC testing for the detection of coronary heart
isease risk has led the National Cholesterol Education Pro-
ram (NCEP) (2), American Heart Association (3), and
merican College of Cardiology (1) to include CAC as a
andidate component of the coronary risk assessment within
ublished guidelines and expert consensus statements. How-
ver, these statements further note that there are no convincing
rom the *Departments of Medicine, Cardiology Service, Walter Reed Army
edical Center, Washington, DC; and the †Uniformed Services University of the
ealth Sciences, Bethesda, Maryland. This work was fully supported by an indepen-
ent, competitive grant award from the federally funded, congressionally directed,
eer Reviewed Medical Research Program, grant number ERMS 00239017-00216.
r. Taylor has worked as a consultant for companies that market statin drugs (Merck
nd Pfizer). He receives grant support from Abbott Pharmaceuticals.A
Manuscript received July 20, 2007; revised manuscript received November 14,
007, accepted November 19, 2007.ata whether CAC screening alters clinical management (such
s the use of preventive medications); thus this remains an
mportant limitation to our understanding the clinical utility of
ardiac computerized tomography as a screening test.
In this report, we present the prospective incidence of
tatin and aspirin usage observed during 6-year actuarial
ollow-up of the PACC (Prospective Army Coronary Cal-
ium) Project cohort and its relationship to coronary heart
isease risk factors and CAC. The principal, pre-specified
im of this analysis was to examine the independent association
etween CAC and subsequent use of pharmacotherapies to
educe cardiovascular risk.
ethods
his protocol was approved by the Department of Clinical
nvestigation of Walter Reed Army Medical Center and
unded under the congressionally directed, peer-reviewed
edical research program of the Department of Defense.
ctive duty Army personnel (n  2,000), ages 40 to 50
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Use of Statin and Aspirin After CAC Screening April 8, 2008:1337–41years old, were recruited for car-
diovascular risk screening and
electron beam computed tomog-
raphy at the time of periodic,
physical examinations as previ-
ously detailed (4). Because of the
low prevalence of CAC in
women in this cohort, this anal-
ysis is limited to male partici-
pants (n  1,640). The relation-
ships among CAC, baseline
oronary risk factors, and outcomes in the PACC Project
ave been previously reported (5–7). The finding of CAC in
ale PACC Project participants has been shown to be
ssociated with an 11.8-fold increased risk for coronary
eart disease events during mean 3-year follow-up (8).
ACC project procedures. Each participant at study entry
rovided details of their medical history, lifestyle behaviors,
nd psychosocial history, and cardiovascular risk factors were
easured (4). Validated instruments were used to assess for
abitual physical activity (4,9); diet (10); general functional
tatus; stress; criteria-based DSM-IV diagnoses of depres-
ion, anxiety, and somatoform disorders; functional status
11); depression; anxiety; and somatization (12). For the
easurement of CAC, electron beam computed tomography
as performed with an Imatron C-150 and C300 LXP
canners (Imatron Corp., South San Francisco, California)
ith the Agatston scoring method (13). A scan was considered
ositive for CAC when the total CAC score was 0.
rospective determination of statin and aspirin usage.
edications for the treatment of cardiovascular risk were
either specifically recommended nor provided under the
tudy protocol. Participants were provided with the CAC
core and measured risk factor values; however, pharmaco-
herapy was neither endorsed nor prescribed by the study
xcept for prespecified extreme blood pressure values. After
he enrollment visit, participants returned to the care of
heir primary care providers who determined all subsequent
linical management. The vital status of the PACC Project
ohort was tracked through annual telephonic contacts,
uring which a structured interview was conducted. Data on
urrent cardiovascular health and medications were recorded
nd medication use was confirmed for completeness through
he use of the military’s electronic health record. Recorded
edications included all commercially available statin med-
cations during the duration of the study and aspirin.
edication usage was classified as either “ever use” or
persistent use.” “Ever use” was determined when a partic-
pant reported usage of a medication on at least 1 follow-up
nterview. “Persistent use” was defined as reported use of a
edication, once initiated, on all subsequent follow-up
ontacts.
tatistical methods. The use of medication across time
ever use and persistent use) and the categorical and time-
ependent relationships between CAC and statin and/or
Abbreviations
and Acronyms
CAC  coronary artery
calcium
LDL-C  low-density
lipoprotein cholesterol
NCEP  National
Cholesterol Education
Programspirin were described. We determined the appropriateness cf statin use with NCEP guidelines and then stratified the
ohort by CAC categories (CAC present or absent). For
nivariate analyses, continuous variables were compared with a
test for independent groups, and categorical variables were
ompared with the chi-square test. We conducted multivari-
ble logistic regression for the dependent variables “ever use” or
persistent use” of medication (statin, aspirin, or both). Inde-
endent variables in this analysis included coronary risk
ariables as specified by the NCEP, CAC-identified as
ategorically present or absent, and other variables of inter-
st with possible impact on medication-taking behavior
depression, somatization, education, income). All analyses
ere performed by expert statisticians (H.W., T.L.) with
PSS for Windows (version 13.0, SPSS Inc., Chicago,
haracteristics of the Study Participants
Table 1 Characteristics of the Study Participants
Men, n 1,640
Age (yrs, mean SD) 42.9 2.8
Caucasian 71.8%
African American 17.8%
College-educated 82.6%
Cardiac risk factors
Hypertension 30.8%
First degree of family history for CHD 18.5%
Either first, second, or both degree of family
history for CHD
31.7%
Metabolic syndrome 6.6%
Current tobacco use 6.9%
Diabetes mellitus 0.8%
10-yr Framingham risk index CHD 4.6 2.6
10-yr Framingham risk index cardiovascular disease 7.3 3.9
CAC score
Mean 19.5 110.7
Median 0
CAC score  0 1,263 (77.6%)
CAC score  1–9 120 (7.4%)
CAC score  10–44 120 (7.4%)
CAC score 45 124 (7.6%)
Baecke Sports index* 3.0 1.0
Body mass index (kg/m2) 27.8 3.5
Waist girth (cm) 95.8 24.9
Systolic blood pressure (mm Hg) 124.3 12.0
Diastolic blood pressure (mm Hg) 77.6 8.8
Total cholesterol (mg/dl) 204.2 36.1
LDL-C (mg/dl) 128.5 31.4
HDL-C (mg/dl) 50.4 12.62
Triglycerides (mg/dl) 129.8 86.5
Fasting glucose (mg/dl) 92.7 11.1
Hemoglobin A1C (%) (n  1,581) 5.4 0.6
Lipoprotein(a) (mg/dl) 30.1 33.5
Homocysteine (mol/l) 9.6 2.5
Fibrinogen (mg/dl) 315.2 58.9
Insulin (U/ml) 8.0 6.0
C-reactive protein (mg/l) 1.9 2.2
alues are expressed as mean SD. C-reactive protein, n  832. *Baecke Sports index score
anges from 1 to 5, 5 being most active.
CAC coronary artery calcium; CHD coronary heart disease; HDL-C high-density lipoprotein
holesterol; LDL-C  low-density lipoprotein cholesterol.
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April 8, 2008:1337–41 Use of Statin and Aspirin After CAC Screeningllinois). Data are presented as mean  SD. A 2-tailed
 value of  0.05 was considered statistically significant.
esults
he prevalence of CAC was 22.4% (367 of 1,640) (Table 1).
t the time of study entry, the use of statin or aspirin was
oted in 94 (5.7%) and 197 (12.0%) participants, respec-
ively. At study entry, those with CAC were significantly
ore likely to be receiving treatment with statins (9.8% vs.
.6%; p  0.001) or aspirin (19.6% vs. 9.8%; p  0.001).
During follow-up, subsequent ever-use of a statin was
oted in 23% of participants, including 48.5% of those with
Figure 1 Incidence of Statin Use During 6-Year
Actuarial Follow-Up in the PACC Project Cohort
Men only; n  1,640. Ever-use of a statin was noted in 23% of participants,
including 48.5% of those with coronary artery calcium and 15.5% of those with-
out coronary artery calcium (p  0.001), which remained significant after con-
trolling for National Cholesterol Education Program risk variables (odds ratio
3.53; 95% confidence interval 2.66 to 4.69).
haracteristics of Participants Stratifiedy Statin Use Over 6 Years in the PACC Project
Table 2 Characteristics of Participants Stratifiedby Statin Use Over 6 Years in the PACC Project
Never on Statin
(n  1,263)
Statin Users
(n  377) p Value
Age (yrs) 42.7 2.6 43.4 2.9 0.001
Prevalence of CAC 16.6% 41.6% 0.001
Mean CAC score 7 40 59 213 0.001
Number of NCEP risk
factors
1.4 1.0 1.8 1.0 0.001
Framingham risk
score (10-yr)
4.2 2.4 6.0 2.9 0.001
Body mass index (kg/m2) 27.6 3.1 28.6 4.5 0.001
Systolic blood
pressure (mm Hg)
124 12 126 12 0.001
Diastolic blood
pressure (mm Hg)
77 9 80 8 0.001
Total cholesterol (mg/dl) 198 33 225 38 0.001
LDL-C (mg/dl) 123 29 146 33 0.001
HDL-C (mg/dl) 51 13 48 12 0.001
Triglycerides (mg/dl) 121 77 160 106 0.001
Hemoglobin A1C (%) 5.4 0.6 5.5 0.7 0.007CEP  National Cholesterol Education Program; PACC  Prospective Army Coronary Calcium;
ther abbreviations as in Table 1. AAC and 15.5% of those without CAC (p  0.001) with
rogressive divergence in the incidence of pharmacotherapy
ver time (Fig. 1). Statin users were significantly different
han statin non-users with respect to all major cardiovascu-
ar risk variables (Table 2). A similar pattern of aspirin use
as noted, with ever-use of aspirin noted in 31.2%, includ-
ng 51.5% of those with CAC versus 25.3% of those without
AC (p  0.001) (Fig. 2). Aspirin users were significantly
ifferent than aspirin non-users with respect to all major
ardiovascular risk variables (Table 3). In multivariable logistic
egression analysis, the presence of CAC was associated with a
- to 7-fold greater likelihood of the use of statin, aspirin,
r both after controlling for NCEP coronary risk factors
Table 4). These odds ratios were not attenuated after
Figure 2 Incidence of Aspirin Use During 6-Year
Actuarial Follow-Up in the PACC Project Cohort
Men only; n  1,640. Ever-use of aspirin was noted in 31.2% of participants,
including 51.5% of those with coronary artery calcium versus 25.3% of those
without coronary artery calcium (p  0.001), which remained significant after
controlling for National Cholesterol Education Program risk variables (odds ratio
3.05; 95% confidence interval 2.30 to 4.05).
haracteristics of Participants Stratifiedy Aspirin Use Over 6 Years in the PACC Project
Table 3 Characteristics of Participants Stratifiedby Aspirin Use Over 6 Years in the PACC Project
Never on Aspirin
(n  1,129)
Aspirin Users
(n  511) p Value
Age (yrs) 42.7 2.7 43.3 2.8 0.001
Prevalence of CAC 15.8% 37% 0.001
Mean CAC score 7 38 47 187 0.001
Number of NCEP risk factors 1.4 1.0 1.6 1.0 0.001
Framingham risk score (10-yr) 4.3 2.5 5.1 2.9 0.001
Body mass index (kg/m2) 27.7 3.7 28.0 3.1 0.001
Systolic blood pressure
(mm Hg)
124 12 126 13 0.001
Diastolic blood pressure
(mm Hg)
77 9 79 9 0.001
Total cholesterol (mg/dl) 202 36 209 37 0.001
LDL-C (mg/dl) 127 32 141 101 0.001
HDL-C (mg/dl) 51 13 50 12 0.001
Triglycerides (mg/dl) 124 78 141 102 0.001
Hemoglobin A1C (%) 5.4 0.6 5.4 0.7 0.007bbreviations as in Tables 1 and 2.
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Use of Statin and Aspirin After CAC Screening April 8, 2008:1337–41ontrolling for additional variables including depression,
omatization, fitness, diet, income, and education.
We evaluated, among subjects not treated with statins at
he time of entry into the study (n  1,546), the initiation
f statin medications during follow-up stratified by baseline
CEP low-density lipoprotein cholesterol (LDL-C) goal
tatus and CAC categories. A total of 469 subjects (30.9%)
ere not at NCEP Adult Treatment Panel III LDL-C goal
t study entry. Among these subjects, the proportion pre-
cribed a statin during follow-up was significantly higher for
hose with CAC (66 of 110; 55.0%) than those without
AC (108 of 347, 31.1%; p  0.001). Similarly, among
ubjects with a baseline LDL-C at NCEP goal, a greater
roportion received a statin in follow-up (55 of 211; 26.1%)
han those without CAC (54 of 868; 6.2%; p  0.001).
The persistence of statin and aspirin use was examined in
elation to the presence or absence of coronary calcium.
oronary calcium was not associated with a significantly
reater persistence of either medication. Specifically, persis-
ent statin use was observed in 86.6% (136 of 157) with
AC versus 79.1% (174 of 220; p  0.06) of those without.
imilarly, persistent aspirin use was observed in 79.4% (150
f 189) with CAC versus 82.6% (266 of 322; p  0.36) of
hose without. Significant differences in medication persis-
ence were not observed in multivariable analysis after adjust-
ent for the number of NCEP risk factors present or depres-
ion, somatization, fitness, diet, income, and education.
iscussion
he PACC Project findings on medication use indicate that
he identification of CAC substantially increases the pro-
ortion of subjects treated over time with aspirin, statin, or
oth. These findings from a community-based cohort of
onreferred study participants provide the first demonstra-
ion of an independent impact of anatomic-based subclini-
al atherosclerosis screening on patient management and
end additional support to recent recommendations for use
f CAC testing to refine the cardiovascular risk assessment
1–3). Notably this association was incremental to and
uantitatively stronger than the association of use of these
Multivariable Logistic Regression Models DemoCAC With Subsequent Medication Usage With aRisk F ctors
Table 4
Multivariable Logistic Regression M
CAC With Subsequent Medication U
Risk Factors
Dependent Variable
CAC
Odds Ratio
Statin use 3.53 (2.66–4.69)
Aspirin use 3.05 (2.30–4.05)
Statin and aspirin use 6.97 (4.81–10.10)
Persistent use of statin 1.71 (0.97–3.00)
Persistent use of aspirin 0.80 (0.51–1.27)
Excluding baseline users of statin and/or aspirin.
Abbreviations as in Tables 1 and 2.edications with NCEP risk variables.
2Despite these findings, preventive medications were still
nderused, as previously recognized in both primary and
econdary prevention (14). Also, we found increased use of
tatin among individuals who had achieved their NCEP
DL-C goal, suggesting intensification of treatment be-
ond that recommended in current lipid treatment guide-
ines. Although there is interest in CAC identification as a
otivational tool, the data to date suggest against an effect
f CAC on long-term patient behavior (15). Consistent
ith this, our study did not find an association between
AC and medication persistence. A motivational effect of
AC is conceptually attractive, but medication persistence is a
omplex phenomenon determined less by a single health care
nteraction (a CAC scan) than by numerous factors over time
n a longitudinal provider-patient relationship (15–18).
The military health care system is a large closed system of
are that provides comprehensive and accessible health care
nd access to medications without insurance or cost barriers
hat might influence medication use patterns. The healthy
ohort studied herein is notable for several unique charac-
eristics, including generally low coronary calcium scores,
igh levels of medication persistence, and possibly higher
evels of motivation to follow a healthy lifestyle. Although we
elied on self-reported medication use, these were identified
hrough a structured medical interview and were verifiable
hrough electronic pharmacy records.
onclusions
he presence of coronary calcification was associated with
n independent 3-fold greater likelihood of statin and
spirin usage and more appropriate use of statins during
-year follow-up within the PACC Project cohort. These
ndings support the concept that the identification of
oronary calcium in a screening population leads to shifts in
linical patient management reflected in the provision of
reventive cardiovascular pharmacotherapies.
eprint requests and correspondence: Dr. Allen J. Taylor, Chief,
ardiology Service, Walter Reed Army Medical Center, 6900
eorgia Avenue NW, Building 2, Room 4A34, Washington, DC
ting the Association of Baselineithout Controlling for NCEP
s Demonstrating the Association of Baseline
With and Without Controlling for NCEP
NCEP Risk Factors
p Value Odds Ratio p Value
0.001 1.37 (1.20–1.57) 0.001
0.001 1.25 (1.10–1.42) 0.001
0.001 1.52 (1.27–1.82) 0.001
0.06 1.17 (0.89–1.55) 0.26
0.35 1.07 (0.86–1.32) 0.54nstrand W
odel
sage0307-5001. E-mail: allen.taylor@na.amedd.army.mil.
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